Overview

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

Status:
Withdrawn

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

The combination of capecitabine and cetuximab as first-line therapy will result in improved progression free survival compared to single agent capecitabine in patients with KRAS wild type colorectal cancer. Patients who are not able or willing to take Oxaliplatin/Irinotecan combination therapy are eligible for this study.

Phase:

Phase 2

Details

Lead Sponsor:

Translational Drug Development

Collaborators:

Eli Lilly and Company
ImClone LLC

Treatments:

Capecitabine
Cetuximab